title: Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant.
abstract: Evidence of long-term response to lenalidomide in heavily pretreated patients with multiple myeloma is lacking. This study sought to assess whether long-term responders exist, long-term responders' characteristics, and predictive factors of a long-term response. One hundred and four patients with multiple myeloma treated with lenalidomide and dexamethasone after ≥2 therapy lines (median, 3) were analyzed. Long-term response was defined as at least a partial response (≥PR) lasting ≥12 months. The overall response rate was 73%, and 80.3% of the responses were achieved within 5 months. The median response was 14.3 months. Patients evaluable for long-term response numbered 87, and a total of 47% were long-term responders. Compared to non-long-term responders, long-term responders had better overall survival, less light-chain multiple myeloma, and higher incidence of t(11;14). Previous allogeneic transplant (alloSCT) and the response quality predicted a long-term response. In conclusion, patients treated with lenalidomide can become long-term responders; alloSCT and response quality predict long-term response.
authors.affiliation: Divisione di Ematologia-Trapianto di Midollo Osseo, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. francesco.spina@istitutotumori.mi.it
authors.forename: Francesco
authors.initials: F
authors.lastname: Spina
authors.forename: Vittorio
authors.initials: V
authors.lastname: Montefusco
authors.forename: Claudia
authors.initials: C
authors.lastname: Crippa
authors.forename: Annalisa
authors.initials: A
authors.lastname: Citro
authors.forename: Simona
authors.initials: S
authors.lastname: Sammassimo
authors.forename: Barbara
authors.initials: B
authors.lastname: Olivero
authors.forename: Silvia
authors.initials: S
authors.lastname: Gentili
authors.forename: Monica
authors.initials: M
authors.lastname: Galli
authors.forename: Tommasina
authors.initials: T
authors.lastname: Guglielmelli
authors.forename: Davide
authors.initials: D
authors.lastname: Rossi
authors.forename: Antonietta Pia
authors.initials: AP
authors.lastname: Falcone
authors.forename: Mariella
authors.initials: M
authors.lastname: Grasso
authors.forename: Francesca
authors.initials: F
authors.lastname: Patriarca
authors.forename: Marianna
authors.initials: M
authors.lastname: De Muro
authors.forename: Paolo
authors.initials: P
authors.lastname: Corradini
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003582:Cytogenetics; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007132:Immunoglobulin Isotypes / Q000276:immunology; D000077269:Lenalidomide; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D012008:Recurrence; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007132:Immunoglobulin Isotypes; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide